Clinical trials Clinical trials Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (Cancer - Recruitment: OPEN) Project Title A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors. Official Title A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors. Project Summary The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D), safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; and in combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors. Blood Disorder Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma Patient Recruitment Details Patient recruitment status: Open Number of Patients (Globally) 150 participants.